The PaceNew therapies / indications available since the last 12 months 
Steglujan
BY: Olive TseJun 15, 2020

Steglujan

(ertugliflozin/sitagliptin) MSD

 

Composition:

  • Available in tablet with each contains 15 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 100 mg sitagliptin (as sitagliptin phosphate monohydrate)

 

Indication:

  • As an adjunct to diet and exercise to improve glycaemic control in adults aged 18 years and older with type 2 diabetes mellitus:
  • when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control
  • in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets

 

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.

You May Be Interested In
ELUNATE®
BY: Eura SoJun 20, 2024
Trodelvy
BY: Winnie TangDec 18, 2023
Darzalex
BY: Olive TseSep 16, 2020